JP2021042257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021042257A5 JP2021042257A5 JP2020209835A JP2020209835A JP2021042257A5 JP 2021042257 A5 JP2021042257 A5 JP 2021042257A5 JP 2020209835 A JP2020209835 A JP 2020209835A JP 2020209835 A JP2020209835 A JP 2020209835A JP 2021042257 A5 JP2021042257 A5 JP 2021042257A5
- Authority
- JP
- Japan
- Prior art keywords
- binding factor
- bcma
- bispecific
- domain
- bispecific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 12
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 12
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- 210000004027 cells Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102100001249 ALB Human genes 0.000 claims 2
- 101710027066 ALB Proteins 0.000 claims 2
- 210000004011 Plasma Cells Anatomy 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 206010002022 Amyloidosis Diseases 0.000 claims 1
- 206010002023 Amyloidosis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 102100014838 FCGRT Human genes 0.000 claims 1
- 101710003435 FCGRT Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- -1 Fv molecule Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006822 Human Serum Albumin Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 208000003359 Plasma Cell Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 101000551314 TNFRSF17 Proteins 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 102000037911 human TNFRSF17 protein Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 claims 1
Claims (22)
- 第一の結合ドメイン及び第二の結合ドメインを含む二重特異性結合因子であって、前記第一の結合ドメインがヒトB細胞成熟抗原（BCMA）と結合し、さらに前記第二の結合ドメインがヒトCD3と結合し、前記BCMA結合ドメインのKD値が前記CD3結合ドメインのKD値よりも低い、前記二重特異性結合因子。
- 第一の結合ドメインが標的細胞上で発現しているヒトBCMAに結合し、第二の結合ドメインが同時にT細胞上で発現しているヒトCD3に結合する、請求項１記載の二重特異性結合因子。
- BCMA結合ドメインのKD値が10 -7 〜5ｘ10 -9 Mの範囲である、請求項１または２記載の二重特異性結合因子。
- CD3結合ドメインのKD値が10 -6 〜5ｘ10 -9 Mの範囲である、請求項１〜３のいずれか１項記載の二重特異性結合因子。
- 第一の結合ドメインが、カニクイザル又はアカゲザルBCMAと交差反応性を示す、
請求項１〜４のいずれか１項記載の二重特異性結合因子。 - 第二の結合ドメインがヒトCD3のε鎖に結合する、請求項１〜５のいずれか１項記載の二重特異性結合因子。
- 第二の結合ドメインが、ヒトCD3のε鎖の最初のN-末端27アミノ酸または前記27アミノ酸ストレッチの機能的フラグメントに一致するエピトープに結合する請求項１〜６のいずれか１項記載の二重特異性結合因子。
- 完全長抗体、抗体様分子、抗体鎖、抗体ドメイン、ジアボディ、単一ドメイン抗体、単鎖抗体、Fv分子、または抗体フラグメントを含む、請求項１〜７のいずれか１項記載の二重特異性結合因子。
- 抗体定常ドメインの一部を含む、または抗体定常ドメインを欠く、請求項１〜８のいずれか１項記載の二重特異性結合因子。
- 新生Fcレセプター（FcRn）と結合する領域を含む、請求項１〜９のいずれか１項記載の二重特異性結合因子。
- リンカーペプチドを介して、又はヒト血清アルブミン分子を介して連結された2つのscFv分子を含むまたは前記scFv分子からなる二重特異性単鎖抗体の形態である、請求項１〜１０のいずれか１項記載の二重特異性結合因子。
- 可変重鎖領域（VH）及び対応する可変軽鎖領域（VL）が、N-末端からC-末端へ以下の順序で編成される、請求項１１に記載の二重特異性結合因子：
VH(BCMA)−VL(BCMA)−VH(CD3)−VL(CD3)、
VH(CD3)−VL(CD3)−VH(BCMA)−VL(BCMA)、又は
VH(CD3)−VL(CD3)−VL(BCMA)−VH(BCMA)。 - アルブミン結合成分を含む、請求項１〜１２のいずれか１項記載の二重特異性結合因子。
- アルブミン結合成分が抗アルブミン免疫グロブリン単一可変ドメインである、請求項１３記載の二重特異性結合因子。
- 第一の結合ドメインおよび第二の結合ドメインが同一形態又は異なる形態を有する、請求項１〜１４のいずれか１項記載の二重特異性結合因子。
- 請求項１〜１５のいずれか１項記載の二重特異性結合因子をコードする核酸分子。
- １以上の請求項１６記載の核酸分子を含む宿主細胞。
- 請求項１〜１５のいずれか１項記載の二重特異性結合因子を作製する方法であって、
請求項１７記載の宿主細胞を、二重特異性結合因子又はそのフラグメントの発現を可能にする条件下で培養する工程、
前記宿主細胞によって発現された二重特異性結合因子を培養物から回収又は単離する工程、
を含む前記方法。 - 請求項１から１５のいずれか１項に記載の二重特異性結合因子の少なくとも1つを含む医薬組成物。
- 形質細胞異常、BCMA発現と相関性を有する他のB細胞異常、又は自己免疫疾患の治療のための、請求項１９に記載の医薬組成物。
- 形質細胞腫、形質細胞白血病、多発性骨髄腫、マクログロブリン血症、アミロイド症、ヴァルデンストレームマクログロブリン血症、孤立性骨形質細胞腫、骨髄外形質細胞腫、骨硬化性骨髄腫、重鎖疾患、意味不明の単クローン性高ガンマグロブリン血症、くすぶり型多発性骨髄腫から選択される形質細胞異常の治療のための、請求項１９に記載の医薬組成物。
- 他の１以上の追加の治療薬剤と併用される、請求項２０または２１記載の二重特異性結合因子または医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10191418.2 | 2010-11-16 | ||
| EP10191418 | 2010-11-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018224988A Division JP2019030338A (ja) | 2010-11-16 | 2018-11-30 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021042257A JP2021042257A (ja) | 2021-03-18 |
| JP2021042257A5 true JP2021042257A5 (ja) | 2021-05-06 |
Family
ID=43769116
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539249A Pending JP2014500879A (ja) | 2010-11-16 | 2011-11-16 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| JP2016234174A Pending JP2017093437A (ja) | 2010-11-16 | 2016-12-01 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| JP2018224988A Pending JP2019030338A (ja) | 2010-11-16 | 2018-11-30 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| JP2020209835A Pending JP2021042257A (ja) | 2010-11-16 | 2020-12-18 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539249A Pending JP2014500879A (ja) | 2010-11-16 | 2011-11-16 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| JP2016234174A Pending JP2017093437A (ja) | 2010-11-16 | 2016-12-01 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
| JP2018224988A Pending JP2019030338A (ja) | 2010-11-16 | 2018-11-30 | Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130273055A1 (ja) |
| EP (2) | EP3974453A3 (ja) |
| JP (4) | JP2014500879A (ja) |
| WO (1) | WO2012066058A1 (ja) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| EP3415531B1 (en) * | 2011-05-27 | 2023-09-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| AU2013340799B2 (en) | 2012-11-01 | 2018-08-09 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| WO2014122144A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| EP2961773B1 (en) * | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| CA2904230A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| US20160022813A1 (en) * | 2013-03-13 | 2016-01-28 | Sanofi | Compositions comprising anti-cd38 antibodies and carfilzomib |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| KR102480433B1 (ko) | 2014-02-07 | 2022-12-21 | 맥마스터 유니버시티 | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 |
| ES2861600T3 (es) * | 2014-04-04 | 2021-10-06 | Mayo Found Medical Education & Res | Isotipaje de inmunoglobulinas usando masa molecular precisa |
| SG11201608415QA (en) * | 2014-04-30 | 2016-11-29 | Max Delbrück Ct Für Molekulare Medizin In Der Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| SG10201900931XA (en) * | 2014-12-05 | 2019-02-27 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| AU2015357533B2 (en) | 2014-12-05 | 2021-10-07 | Eureka Therapeutics, Inc. | Antibodies targeting B-cell maturation antigen and methods of use |
| EP3757128A1 (en) | 2015-04-13 | 2020-12-30 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| CA2925329C (en) | 2015-04-13 | 2024-01-02 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
| JP7163028B2 (ja) * | 2015-05-13 | 2022-10-31 | アブリンクス エン．ヴェー． | Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド |
| ES2889906T3 (es) | 2015-05-21 | 2022-01-14 | Harpoon Therapeutics Inc | Proteínas de unión triespecíficas y usos médicos |
| WO2016196612A1 (en) * | 2015-06-01 | 2016-12-08 | The Rockefeller University | Anti-tumor agents and methods of use |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA036975B1 (ru) | 2015-08-03 | 2021-01-21 | Энгмаб Сарл | Моноклональные антитела против bcma |
| MA53750A (fr) | 2015-08-17 | 2021-09-15 | Janssen Pharmaceutica Nv | Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations |
| TWI797073B (zh) * | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | 包含雙特異性抗體建構物之醫藥組合物 |
| CR20180420A (es) * | 2016-02-03 | 2018-12-05 | Amgen Inc | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| DK3411404T3 (da) | 2016-02-03 | 2023-01-30 | Amgen Res Munich Gmbh | Psma- og cd3-bispecifikke t-celleinddragende antistofkonstruktioner |
| BR112018016697A2 (pt) | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento. |
| EA201892691A1 (ru) | 2016-05-20 | 2019-04-30 | Харпун Терапьютикс, Инк. | Однодоменный белок, связывающий сывороточный альбумин |
| CA3024683A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| CN109843325B (zh) | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
| EP4295918A3 (en) * | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3541846A1 (en) * | 2016-11-16 | 2019-09-25 | Ablynx NV | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| AU2017363302A1 (en) | 2016-11-23 | 2019-06-27 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
| CN110913908B (zh) | 2017-05-12 | 2022-05-27 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
| JP2020523383A (ja) | 2017-06-14 | 2020-08-06 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）指向性ナノ粒子 |
| CN117866097A (zh) | 2017-06-20 | 2024-04-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
| EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| PT3681483T (pt) * | 2017-09-15 | 2022-08-22 | Amgen Inc | Processo para formulação farmacêutica liofilizada de uma proteína terapêutica |
| WO2019064263A1 (en) * | 2017-09-29 | 2019-04-04 | Janssen Biotech, Inc. | NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS |
| US11643472B2 (en) | 2017-10-12 | 2023-05-09 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
| CR20200196A (es) | 2017-10-13 | 2020-06-05 | Harpoon Therapeutics Inc | Proteínas trispecìficas y mètodos de uso |
| CN111465612A (zh) * | 2017-10-13 | 2020-07-28 | 哈普恩治疗公司 | B细胞成熟抗原结合蛋白 |
| CN111629749A (zh) | 2017-10-18 | 2020-09-04 | 诺华股份有限公司 | 用于选择性蛋白质降解的组合物和方法 |
| WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法 |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| JP7486421B2 (ja) | 2017-12-22 | 2024-05-17 | テネオバイオ， インコーポレイテッド | Ｃｄ２２に結合する重鎖抗体 |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112119099A (zh) | 2018-03-02 | 2020-12-22 | Cdr-生物科技股份有限公司 | 三特异性抗原结合蛋白 |
| JOP20200292A1 (ar) | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
| TW202016139A (zh) | 2018-06-13 | 2020-05-01 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| KR102597053B1 (ko) * | 2018-06-26 | 2023-11-02 | 에이비엘바이오 주식회사 | 항-bcma 항체 및 그 용도 |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| MA53168A (fr) | 2018-07-19 | 2021-05-26 | Regeneron Pharma | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations |
| MX2021002393A (es) | 2018-08-31 | 2021-07-15 | Novartis Ag | Metodos de preparacion de celulas que expresan receptores de antigenos quimericos. |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| PE20211867A1 (es) * | 2018-11-01 | 2021-09-21 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpos biespecificos y su uso |
| MX2021010150A (es) | 2019-02-25 | 2021-09-14 | Novartis Ag | Composiciones de particulas de silice mesoporosa para administracion viral. |
| US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
| FI4058148T3 (fi) * | 2019-11-11 | 2024-05-06 | Amgen Res Munich Gmbh | Annosteluohjelma anti-bcma-aineille |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| MX2022010175A (es) | 2020-02-21 | 2022-09-12 | Harpoon Therapeutics Inc | Proteinas de union a flt3 y metodos de uso. |
| MX2022010685A (es) | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
| EP4110376A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| CR20230149A (es) | 2020-04-29 | 2023-05-25 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539) |
| IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Treatment methods for multiple myeloma |
| TW202207977A (zh) | 2020-05-19 | 2022-03-01 | 美商健生生物科技公司 | 包含ｔ細胞重導向治療劑及ｖｌａ－４黏附路徑抑制劑之組成物 |
| CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| JP2023538118A (ja) | 2020-08-21 | 2023-09-06 | ノバルティス アーゲー | Ｃａｒ発現細胞のインビボ生成のための組成物及び方法 |
| US20240117061A1 (en) * | 2020-12-16 | 2024-04-11 | Wuhan Yzy Biopharma Co., Ltd. | Anti-bcma antibody, preparation method therefor and application thereof |
| JP2024506831A (ja) | 2021-01-28 | 2024-02-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイトカイン放出症候群を治療するための組成物及び方法 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| WO2023021477A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| ATE168272T1 (de) | 1989-10-27 | 1998-08-15 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) * | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| CA2335364C (en) * | 1998-06-22 | 2010-05-04 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| DE60042617D1 (de) | 1999-01-07 | 2009-09-03 | Zymogenetics Inc | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| JP2004531217A (ja) * | 2001-01-05 | 2004-10-14 | ファイザー・インク | インスリン様成長因子ｉ受容体に対する抗体 |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| EP2301971A1 (en) * | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1314741B1 (en) | 2001-11-14 | 2007-03-07 | Affimed Therapeutics AG | Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof |
| US8784821B1 (en) | 2003-05-31 | 2014-07-22 | Amgen Research (Munich) Gmbh | Human-anti-human cd3 binding molecules |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
| CN100453556C (zh) | 2003-10-16 | 2009-01-21 | 麦克罗梅特股份公司 | 多特异性的去免疫化cd3结合物 |
| US20070249530A1 (en) * | 2004-01-29 | 2007-10-25 | Genentech, Inc. | Bcma Polypeptides and Uses Thereof |
| JP4812748B2 (ja) * | 2004-04-06 | 2011-11-09 | ノビミューン エスアー | 自己免疫性疾患および炎症性疾患を処置する方法 |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
| US7910703B2 (en) * | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| SG172698A1 (en) * | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| CA2659225A1 (en) | 2006-07-26 | 2008-01-31 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
| SI2155788T1 (sl) * | 2007-04-03 | 2012-11-30 | Amgen Res Munich Gmbh | Bispecifični vezavni element specifičen za križane vrste |
| EP3461842A1 (en) | 2007-04-03 | 2019-04-03 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| WO2009109572A2 (en) | 2008-03-03 | 2009-09-11 | Ablynx Nv | Monovalent phage display of single variable domains |
| US20110091462A1 (en) | 2008-03-05 | 2011-04-21 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
| CA2720682A1 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| CN102292351A (zh) * | 2008-11-26 | 2011-12-21 | 葛兰素集团有限公司 | 结合il-13的配体 |
| WO2010104949A2 (en) * | 2009-03-10 | 2010-09-16 | Biogen Idec Ma Inc. | Anti-bcma antibodies |
-
2011
- 2011-11-16 JP JP2013539249A patent/JP2014500879A/ja active Pending
- 2011-11-16 US US13/885,646 patent/US20130273055A1/en active Pending
- 2011-11-16 EP EP21183531.9A patent/EP3974453A3/en active Pending
- 2011-11-16 EP EP11782175.1A patent/EP2640750A1/en not_active Withdrawn
- 2011-11-16 WO PCT/EP2011/070301 patent/WO2012066058A1/en active Application Filing
-
2016
- 2016-12-01 JP JP2016234174A patent/JP2017093437A/ja active Pending
-
2018
- 2018-11-30 JP JP2018224988A patent/JP2019030338A/ja active Pending
-
2020
- 2020-12-18 JP JP2020209835A patent/JP2021042257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021042257A5 (ja) | ||
| JP7457764B2 (ja) | ヘテロ二量体多重特異性抗体フォーマット | |
| JP7273135B2 (ja) | 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質 | |
| CN109195993B (zh) | 串联fab免疫球蛋白及其用途 | |
| JP7195929B2 (ja) | 三重特異性および／または三価結合タンパク質 | |
| CN106459182B (zh) | 串联fab免疫球蛋白及其用途 | |
| JP2014158485A5 (ja) | ||
| CN102558355B (zh) | 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法 | |
| US20230016112A1 (en) | Engineered cd25 polypeptides and uses thereof | |
| KR20200013230A (ko) | 적어도 cd3 및 hsa를 표적화하는 헤테로-이량체 다중 특이적 항체 포맷 | |
| CN112969476A (zh) | 多特异性蛋白分子 | |
| JP2015526071A (ja) | ヒトＧｎＲＨ受容体に対するモノクローナル抗体のヒト化形態 | |
| JPWO2022102768A5 (ja) | ||
| JPWO2019175368A5 (ja) | ||
| Lombana et al. | Characterization of Bispecific or Other Hybrid Molecules | |
| NZ807450A (en) | Antibodies binding to gprc5d | |
| JPWO2021162098A5 (ja) |